B+
Bull case
20%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
PLX
Protalix BiotherapeuticsANYSE American / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
55%
Probability
Target price
$3.20
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$1.70
Analysis reference price unavailable
Analysis 2026-09-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-07
Recent news sentiment (30D)
+0.6
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+77.9
Score
AI commentary
Recent coverage is constructive around Q2 results, Elfabrio growth, reaffirmed guidance, and PRX-115 progress. However, PLX is low coverage, social coverage is absent, and analyst revision and market-reaction data are unavailable. The evidence supports a monitoring-oriented speculative thesis rather than a high-conviction rerating call.
RankAlpha Sentiment Codex - 2026-09-07
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventPRX-115 Phase 2 enrollment progressHigh impact
The RELEASE Phase 2 study continues enrollment, with stored earnings-call context indicating management expects enrollment completion by year-end 2026 [#PR-EARNINGS-2026-08-14].
2026-12-31catalystElfabrio commercial execution and 2026 guidanceHigh impact
Q2 revenue from selling goods reached $19.8 million, total first-half revenue reached $53.6 million including the Chiesi milestone, and management reiterated full-year 2026 revenue guidance of $78-$83 million [#SEC-8K-2026-08-12].
2027-09-07catalystPRX-115 Phase 2 top-line readoutHigh impact
The company anticipates top-line results from the RELEASE Phase 2 trial in the second half of 2027, creating a potentially material but binary clinical catalyst [#SEC-8K-2026-08-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-07 • Updated nightlySource: Internal modelMethodology